2[1]Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Na ture, 1988,332:411-415.
3[2]Advenier C, Sarria B, Naline E, et al. Contractile activity of three endothelins (ET-1, ET-2 and ET-3 ) on the human isolated bronchus. Br J Pharmacol, 1990,100:168-172.
4[3]Kraft M, Beam WR, Wenzel SE, et al. Blood and bronchoalveolar lavage endothelin-1 levels in nocturnal asthma. Am J Respir Crit Care Med, 1994, 149:946-952.
5[4]Uchida Y, Ninomiya H, Saotome M, et al. Endothelin, a novel vasoconstrictor peptide,as potent bronchoconstrictor. Eur J Phar macol, 1988,154:227-228.
6[5]Goldie RG, Henry PJ, Knott PG, et al. Endothelin-1 receptor density, distribution, and function in human isolated asthmatic air ways. Am J Respir Crit Care Med, 1995,152:1653-1658.
7[6]Clozel M, Breu V, Gray GA, et al. Pharmacological characteriza tion of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther, 1994,270:228-235.
8[7]Finsnes F, Skj φ nsberg OH, T φ nnessen T, et al. Endothelin production and effects of endothelin antagonism during experimen tal airway inflammation. Am J Respir Crit Care Med, 1997,155:1404-1412.
